A low pH was assumed to be required for the activity of pyrazinoic acid (the active form of pyrazinamide) against Mycobacterium tuberculosis, but recently activity has been demonstrated at neutral pH. Renewed interest in pyrazinamide has led to an increasing number of potential targets and the suspicion that pyrazinamide is a 'dirty drug'. However, it is our opinion that the recent demonstration that pyrazinoic acid is active against PanD provides an alternative explanation for the secret of pyrazinamide's unusual activity. In this article we propose that PanD is the primary target of pyrazinoic acid but expression of pyrazinoic acid susceptibility requires an intact stress response. As the mycobacterial stress response requires the interaction of a number of genes, disruption of any could result in an inability to enter the susceptible phenotype. We believe this model can explain most of the recent observations of the seemingly diverse spectrum of activity of pyrazinamide.
Introduction
Pyrazinamide allowed the treatment of fully antibiotic-susceptible TB to be shortened to 6 months while still achieving acceptably low relapse rates. 1 The impact of pyrazinamide on a lasting cure with newer regimens has been less clear, but recent evidence suggests that resistance to pyrazinamide also results in poorer outcomes for patients with MDR and XDR tuberculosis. 2, 3 However, the effect of pyrazinamide resistance alone seemed to have minimal impact on treatment success with a new shorter course regimen for MDR-TB. 4 As an older drug that is still a component of all current TB regimens, and most new ones under development, it is shocking that the exact mechanism of action of pyrazinamide remains unresolved. Pyrazinamide is difficult to work with as it is not active in standard laboratory culture and it is yet to be established in detail exactly which state(s) mycobacterial cells need to be in to be susceptible to pyrazinamide in the host. This situation is unacceptable and probably reflects the relatively neglected status of Mycobacterium tuberculosis research in recent decades. Nonetheless, it is encouraging that there is renewed interest in this drug from numerous groups, partly because of the introduction of promising new drugs and associated pyrazinamide-containing regimens to treat MDR and XDR [M(X)DR] TB.
Limits of the existing model
In 2003, one of the most widely accepted explanations for the unusual activity of pyrazinamide was proposed. 5, 6 In this model the active form of the drug, pyrazinoic acid, acts as a proton ionophore under extracellular acidic conditions resulting in a loss of cellular membrane potential. 6 A key assumption is that pyrazinoic acid is the active form of pyrazinamide and that pyrazinamide is converted to the active form by the mycobacterial enzyme PncA. This is entirely consistent with the observation that the vast majority of resistant clinical isolates have mutations in the pncA gene and any mutation that disrupts the ability of PncA to convert pyrazinamide into pyrazinoic acid 7 leads to in vitro resistance. 8 More recently, the second core assumption of the Zhang model, the requirement for a low extracellular bacterial pH to activate pyrazinoic acid, has been questioned and the role of pyrazinoic acid as an ionophore as well as the role of cytoplasmic acidification as the lethal mechanism is no longer convincing. 9, 10 As a result, a series of additional targets (discussed in detail below) have been proposed in an attempt to obtain a more comprehensive explanation for the complex activity of pyrazinamide. Although the activity of pyrazinamide/pyrazinoic acid is indeed manifested under acidic conditions, clearly other stresses can also induce a susceptible phenotype. 9, 10 As the experimental data show that an acidic extracellular pH is not a requirement for the in vitro action of pyrazinoic acid, at least under some growth conditions, pyrazinoic acid must have an alternative mechanism of action. It is striking that the common denominator of all papers demonstrating pyrazinamide/pyrazinoic acid activity at non-acidic pH is that activity is exerted under conditions causing a stress response in the M. tuberculosis cells, similar to the stress response triggered by a reduction of the pH. Therefore, we see no particular reason to assume a unique mechanism is induced by low extracellular pH and hypothesize that all these stressors lead to a mycobacterial phenotypic switch towards a state under which the target of pyrazinoic acid is essential for the growth of M. tuberculosis. The 'rather unpredictable' effects of this prodrug in vitro combined with the rather high active concentrations of pyrazinamide (breakpoint 50 mg/L) have led to the idea that pyrazinamide is a so-called 'dirty drug' 11 that impacts numerous targets. This concept of course also fits with most of the in vivo data but recent results make this model increasingly complex. Based on the similarities between the conditions under which the drug is active against mycobacteria, all of which stress the bacteria in some way, our proposal is that pyrazinoic acid inhibits a single target under all conditions but this target is only essential to the bacteria under specific circumstances. Here we review recent data from multiple groups that, in our opinion, support this hypothesis.
Resistance to pyrazinoic acid
That pyrazinoic acid is the active form of pyrazinamide is generally accepted, and strongly supported by the fact that in the vast majority of clinical and laboratory mutants resistance is due to the inability of the mycobacterium to generate pyrazinoic acid because of an inactivating mutation or deletion in pncA. 8 Thus, generating mutants resistant to pyrazinoic acid (rather than pyrazinamide) should bring us closer to the target of pyrazinoic acid. This is technically challenging, as the conditions at which pyrazinamide/pyrazinoic acid is active are suboptimal for growing TB and growth inhibition by pyrazinoic acid is seldom complete. Despite these challenges, mutants selected on pyrazinoic acid-containing medium have recently been reported by multiple groups. All groups report mutations in panD [11] [12] [13] [14] and most also in clpC. 11, [13] [14] [15] We have also generated mutants to pyrazinoic acid at neutral pH and reduced temperature 16 and obtained panD and clpC mutations (A. den Hertog, 2016, personal communication). The fact that mutations in similar genes were generated under different conditions, including acidic and non-acidic conditions, supports our hypothesis that low pH and other stress conditions induce susceptibility by the same mechanism.
panD is a target for pyrazinoic acid Although the role of panD (encoding aspartate decarboxylase) has been questioned 12 a major recent advance in our understanding of the activity of pyrazinoic acid was the demonstration that panD is indeed inhibited by pyrazinoic acid and the mutations generated in vitro after selection with pyrazinoic acid that also result in pyrazinamide resistance. 17 Combined with the fact that panD mutations associated with pyrazinamide resistance have been identified in clinical isolates, 18 this is clear evidence that panD is an important target for pyrazinoic acid also in vivo. This view is supported by the finding that there are M. tuberculosis isolates from a specific evolutionary branch that are naturally resistant to pyrazinamide owing to mutations in panD.
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Bacterial stress and the switch to a pyrazinoic acid-susceptible phenotype: roles for clpC, rpsA and gpsI As noted above, clpC mutations have been selected in vitro after exposure of M. tuberculosis to pyrazinoic acid by multiple groups but as far as we are aware they have yet to be associated with pyrazinamide resistance in clinical isolates. Clp proteases are critical for the regulation of stress responses and the induction of particular bacterial phenotypes 19 and in Bacillus subtilis are needed for survival during extreme growth conditions. 20 A role for Clp proteases in the temporal programming of the M. tuberculosis transcriptome has also been demonstrated. 21 Furthermore, it has been shown that in M. tuberculosis a functional Clp gene regulator is required for in vitro reactivation from hypoxia-induced dormancy. 22 The ability of M. tuberculosis to resist external stresses and enter and exit a latent/fat lazy phenotype is probably critical to maintaining an infection and causing disease. 23 Therefore, it is possible that bacteria that become resistant in vitro as a result of clpC mutations are damaged in their ability to enter a stressed phenotype and hence are avirulent in vivo. This supports ClpC proteases as interesting drug targets and compounds such as lassomycin, a disruptor of M. tuberculosis ClpC1 activity. 24 rpsA mutations: a role for trans-translation?
RpsA is involved in trans-translation, a rescue mechanism for stalled ribosomes. Mutations in RpsA have also been associated with increased resistance to pyrazinamide and it has been suggested that pyrazinamide partially exerts its effect by disrupting trans-translation. 25 However, recent elegant work studying the phenotype of laboratory-generated rpsA mutants and transtranslation did not show any effect of pyrazinamide (pyrazinoic acid) on trans-translation or the expression of RpsA. 26 Confusingly, association studies based on WGS and disc susceptibility testing (DST) appear to confirm a link between rpsA mutations 18,27 as overexpression of rpsA increasing the pyrazinamide MIC. 25 This conflicting information is at first sight difficult to reconcile. Interestingly trans-translation has been closely linked to the stringent response in diverse bacterial species 28 and any disturbances in the balance of these interacting pathways resulting from rpsA mutations, or reduced stress due to increased RpsA activity, could also disrupt entry into a pyrazinamide-susceptible phenotype. Trans-translation may be more involved in the initiation of a stringent response in M. tuberculosis to specific stimuli. Thus, we suggest Dillon et al. 26 are correct that RpsA and trans-translation do not have a role in the mode of action of pyrazinamide and rather that mutations in rpsA reduce the efficiency of a switch to a pyrazinamide-susceptible phenotype.
Another suspect: gpsI
Detailed analysis of four clinical isolates with unexplained resistance to pyrazinamide identified a mutation in Rv2783, a probable guanosine pentaphosphate [(p)ppGpp] synthetase (GpsI). When this Rv2783 mutant gene was expressed in H37Rv it also displayed a resistant phenotype. 29 Fascinatingly (p)ppGpp is a critical signal transducer involved in the stringent response in bacteria. 23 For debate
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Could panD really be the only significant target of pyrazinoic acid?
Entry and exit from latency is critical for M. tuberculosis pathogenicity and under the tight control of multiple feedback loops that might be disrupted by changes to any one of multiple genes. 23 If panD is the primary target of pyrazinamide but susceptibility requires the activation of pyrazinamide to pyrazinoic acid by an unmutated pncA gene and the interaction of clpC, rpsA, gpsI and probably other genes to activate a susceptible bacterial phenotype (Figure 1 ), this would appear to provide a fully coherent model. We believe this model can explain many of the otherwise confusing aspects of pyrazinamide resistance. Other factors may also play a role: resistance to pyrazinamide does appear to be related to the overexpression of efflux proteins and a number of genes when overexpressed result in low-level resistance to pyrazinamide/pyrazinoic acid. 30 Off-target effects of pyrazinoic acid are also suggested by the work of Dillon et al. 13 However, this finding is not consistent with PanD as a primary target and warrants further investigation. 17 The diversity of pncA mutations in most settings at present remains higher than for resistance mechanisms associated with other drugs. 7, 31 This diversity could also be the result of only partial resistance due to off-target pyrazinamide effects and interestingly, in 2016, Gopal et al. 32 proposed that mutations in the mas and ppsA-E genes, involved in the synthesis of a virulence factor, phthiocerol dimycocerosate, also lead to increased resistance to pyrazinoic acid and related compounds, suggesting an alternative mechanism of action. Although the possibility that pyrazinoic acid inhibits a virulence factor is compelling, others have reported that ppsA-E are involved in cell wall thickening and associated with dormancy. 33 
The host and pyrazinamide
Pyrazinamide is not only converted into the active form by bacterial PncA but also in the liver by microsomal deamidase (into pyrazinoic acid) and then further metabolized by xanthine oxidase (Figure 1 ). It has been speculated that the generation of low levels of pyrazinoic acid by the host might mean pncA mutations do not fully eliminate the activity of pyrazinamide in vivo and when the activity of human xanthine oxidase is inhibited (by dosing with allopurinol) increased levels of circulating pyrazinoic acid do result. 34 It is not known if this increase in circulating host-derived pyrazinoic acid would restore pyrazinamide activity against infecting bacteria with pncA mutations but this is an intriguing possibility. In particular, as almost all pyrazinamide-resistant MDR-TB currently circulating are resistant owing to damaged pncA rather than resistance to the active compound. 8 Another possible explanation for why pyrazinamide is more active in the host would be that it (also) acts directly on the host. This was explored in detail in a series of mouse experiments. 35 These experiments did not detect any activity against infections with Mycobacterium bovis, which is naturally PncA negative and pyrazinamide resistant, indicating any effect of pyrazinamide due to host activity or a direct effect on the host was small in the model used. 35 Furthermore, when immunedeficient athymic nude mice were infected with pncA wild-type (pyrazinamide-susceptible) M. tuberculosis the effect of pyrazinamide was eliminated. This finding is difficult to explain. Although, in the context of this document, it is tempting to speculate that a reduced ability of the host's immune system to attack the infecting mycobacteria resulted in less bacterial stress and a smaller proportion of M. tuberculosis cells entering the pyrazinamide-susceptible phenotype. 
Rapid bacterial growth PanD non-essenƟal
Under 'rich' growth condiƟons panD is non-essenƟal and inhibiƟon by POA has no effect.
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Microsomal deamidase
Xanthine oxidase Inhibited by allopurinol Figure 1 . A schematic illustration of our hypothesis. Assuming PZA . POA directly inhibits PanD activity and PanD is only essential for the bacteria when in a 'stressed phenotype', any mutation that disrupts entry into this phenotype might lead to POA resistance. POA, pyrazinoic acid; PZA, pyrazinamide.
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Implications for pyrazinamide susceptibility testing
According to our proposal, any condition that induces pyrazinamide susceptibility will also stress the bacteria and result in a reduced growth rate. We do not directly question the validity of routine DST testing of M. tuberculosis isolates for susceptibility to pyrazinamide in low-pH media. However, if pH is not the critical factor it may not be the optimal way to stimulate susceptibility in all strains and there is tantalizing evidence that such a discrepancy between in vivo and in vitro susceptibility has been observed. A cluster of MDR M. tuberculosis isolates was reported in Samara, Southern Russia, in 2012 all sharing a single mutation in pncA (Ile6Leu). 36 Almost all of these strains tested were susceptible to pyrazinamide in vitro at low pH. As .50% of MDR-TB isolates in such a setting would be expected to have pncA mutations associated with pyrazinamide resistance, it is striking that none of the .100 isolates from this cluster had additional pncA mutations. 36 This strongly suggests that in fact the Ile6Leu mutation is associated with in vivo resistance that is not efficiently induced in vitro by a low pH, as the authors of the original report also suspected. 35 Isolates from this cluster continue to be identified and in a previous report we analysed one such genetically closely related isolate, also with the Ile6Leu mutation, originating from Georgia. 9 When tested at neutral pH but reduced temperature (28 C) this isolate was resistant to pyrazinamide but susceptible to pyrazinoic acid. 9 This suggests that the low pH used to stimulate pyrazinamide resistance in the most widely used DST assays may not fully replicate the in vivo induction of pyrazinamide susceptibility. In addition, a more diverse range of pncA mutations was generated after treatment in mice than after in vitro selection, supporting this possibility. 37 Others have suggested that panD mutations may also result in low-level pyrazinamide resistance that is not detected by the standard methods.
14 Why are non-pncA mutations so rare?
Mutations in panD that lead to pyrazinoic acid resistance in vitro are rare in vivo 18 and so far to the best of our knowledge clpC mutations associated with pyrazinamide resistance have only been observed in pyrazinoic acid-resistant isolates selected in vitro. This suggests that these mutations are inefficiently selected by pyrazinamide, perhaps owing to a much higher probability of pncA-damaging mutations, and/or they are non-viable, non-transmissible or lack virulence in vivo as discussed above. Both these situations support PanD and ClpC as interesting targets for new drug development, as cross-resistance with pyrazinamide is unlikely and these genes appear to be critical for pathogenicity.
Conclusions
Recently a series of surprising findings relating to the activity of pyrazinamide by multiple groups has been published. We believe that that there are now enough clues available to 'trace the secret cause' of pyrazinamide's unusual activity and encourage the investment of creativity, time, energy and money into solving this long-standing puzzle (Figure 1 ). These findings allow us to reassess long-held assumptions about the activity of pyrazinamide and pyrazinoic acid and we should seize this opportunity.
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